The JUPITER Trial: Responding to the Critics
作者： Paul M Ridker , Robert J Glynn , None
DOI: 10.1016/J.AMJCARD.2010.08.025
关键词:
摘要:
elsevier.com
sci-hub.se 参考文章(37)
Robert J Glynn, Eleanor Danielson, Francisco AH Fonseca, Jacques Genest, Antonio M Gotto Jr, John JP Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen, Børge G Nordestgaard, James Shepherd, James T Willerson, Paul M Ridker, None, A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism The New England Journal of Medicine. ,vol. 360, pp. 1851- 1861 ,(2009) , 10.1056/NEJMOA0900241
Michel de Lorgeril, Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. JAMA Internal Medicine. ,vol. 170, pp. 1032- 1036 ,(2010) , 10.1001/ARCHINTERNMED.2010.184
Paul M. Ridker, Jean MacFadyen, Michael Cressman, Robert J. Glynn, Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein Journal of the American College of Cardiology. ,vol. 55, pp. 1266- 1273 ,(2010) , 10.1016/J.JACC.2010.01.020
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis The Lancet. ,vol. 375, pp. 132- 140 ,(2010) , 10.1016/S0140-6736(09)61717-7
Rosuvastatin in patients with elevated C-reactive protein. The New England Journal of Medicine. ,vol. 360, ,(2009) , 10.1056/NEJMC082574
Eric Y. Yang, Vijay Nambi, Zhengzheng Tang, Salim S. Virani, Eric Boerwinkle, Ron C. Hoogeveen, Brad C. Astor, Thomas H. Mosley, Josef Coresh, Lloyd Chambless, Christie M. Ballantyne, Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. Population : Insights From the ARIC (Atherosclerosis Risk in Communities) Study Journal of the American College of Cardiology. ,vol. 54, pp. 2388- 2395 ,(2009) , 10.1016/J.JACC.2009.10.006
Robert L. Ohsfeldt, Sanjay K. Gandhi, Lee J. Smolen, Marie M. Jensen, Kathleen M. Fox, Alex Gold, Judith Hsia, Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. Journal of Medical Economics. ,vol. 13, pp. 428- 437 ,(2010) , 10.3111/13696998.2010.499758
Stuart J. Pocock, Michael D. Hughes, Estimation issues in clinical trials and overviews. Statistics in Medicine. ,vol. 9, pp. 657- 671 ,(1990) , 10.1002/SIM.4780090612
Paul M Ridker, Jose Torres, None, Reported Outcomes in Major Cardiovascular Clinical Trials Funded by For-Profit and Not-for-Profit Organizations: 2000-2005 JAMA. ,vol. 295, pp. 2270- 2274 ,(2006) , 10.1001/JAMA.295.19.2270
Boris Freidlin, Edward L Korn, Stopping clinical trials early for benefit: impact on estimation. Clinical Trials. ,vol. 6, pp. 119- 125 ,(2009) , 10.1177/1740774509102310